BioPharma Resources

Investigational drug · Phase 3

KYV-101

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis.

Phase 3

Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

13

Any phase or sponsor naming "KYV-101"

First trial start

2024

Aug 28, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "KYV-101", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Multiple Sclerosis, Primary Progressive
  • Multiple Sclerosis, Secondary Progressive
  • Multiple Sclerosis
  • MS
  • Myasthenia Gravis
  • Generalized Myasthenia Gravis

Approved drugs for the same conditions: Multiple sclerosis · Myasthenia gravis · Neurology

Largest trials

Live from ClinicalTrials.gov: studies naming "KYV-101" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 12 on PubMed

Also in development for Multiple Sclerosis, Primary Progressive

  • FenebrutinibRO7010939, GDC-0853Phase 36 trials

    Roche (Genentech) · Relapsing Multiple Sclerosis, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.